BENITIONSClinical Trial Intelligence

Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

2期 提前终止 NCT05301894

适应症Epileptic Encephalopathy, Continuous Spike and Wave During Sleep
分期2期
申办方Neurocrine Biosciences
状态提前终止
受试者人数19 人
干预(药物)NBI-827104
开始日期2022年6月7日
完成日期2025年1月27日
结果公布日2026年2月13日

摘要

The primary objective for this study is to evaluate the long-term safety and tolerability of NBI-827104 in pediatric participants with epileptic encephalopathy with continuous spike-and-wave during sleep (EECSWS).

The Number of Participants With Serious Treatment-emergent Adverse Events (TEAEs)

Up to 884 days of treatment and 4-week safety follow-up (mean duration of exposure was 649.7 days) · Participants

NBI-8271042 Participants

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

全部试验

本页整理自 ClinicalTrials.gov 的公开数据,不构成医疗建议,也不构成投资建议。请务必咨询专业医师。